diet physical*sustained weight loss*interventionist*diet*weight weekly*physical activity*medical monitoring*weight maintenance program*medical care setting*diet choice*ongoing monitoring*comprehensive weight maintenance*group session*total meal replacement*body weight*baseline body weight*high intensity*lifestyle intervention*maintenance counseling*weight maintenance counseling*loss such program*comprehensive weight*meal replacement*intervention*comprehensive weight loss*behavioral*lifestyle program*weight maintenance*replacement*monthly contact*such program*weight loss maintenance*energy deficit*loss goal*weight loss*behavioral therapy*deficit*loss sustained weight*term weight loss*necessary energy*obese*diet physical activity*intensive behavioral lifestyle*health status*loss maintenance program*such intervention*term weight*behavioral lifestyle*body weight weekly*necessary energy deficit*sustained weight*least monthly contact*total meal*trained practitioner*loss maintenance*obese patient*maintenance program*care setting*baseline body*trained interventionists*behavioral strategy*calorie*close medical monitoring*behavioral lifestyle intervention*trained interventionist*calorie diet*overweight*short term*interventionists*diabetes*weight loss goal*short term weight
cigarette smoking*weight loss treatment*weight management program*medical monitoring*severe obesity*retrospective analysis*comorbidities*medical therapy*weight management*small intestine*cohort study*comprehensive weight*lifestyle support*banding*body mass index*management program*alcohol use*bariatric*recent study*gastric banding*effective weight*weight loss*metabolic profile*optimal medical therapy*obese*bmi*loss treatment*comparator*effective weight loss*nonsurgical*bariatric surgery*such study*obese patient*modeling study*longer study*stomach stapling*pharmacological therapy*substance use*lifelong lifestyle*comprehensive weight management*pharmacological*metabolic surgery*nonsurgical subject*lifelong lifestyle support*diabetes*such patient
aglucosidase*diet physical*metformin hydrochloride*diet*anhydrous dextrose*insufficient weight loss*adjunct*lowering medication*physical activity*glucose (dl)-isomer*diabetes provider*contraception*treatment approach*weight loss medication*body mass index*behavioral counseling*behavioral*glucose lowering medication*glucose lowering*efficacy*reproductive year*tolerability*glucophage*successful weight*potential benefit*alternative medication*medication*glucose monohydrate*possible medication*potential risk*weight loss*inhibitor*glucose (beta-d)-isomer*tolerability issue*loss medication*concomitant medication*combination therapy*bmi*diet physical activity*agonist*obese*glucose*male contraception*product label*concomitant*aglucosidase inhibitor*insufficient weight*metformin*obese patient*female contraception*glucose (l)-isomer*successful weight loss*reliable method*pharmacological treatment*alpha glucosidase*pharmacological*overweight*glucose (alpha-d)-isomer*diabetes
metformin hydrochloride*activity goal*rate gfr*filtration rate*physical activity*glycemic goal*glomerular filtration rate*monotherapy*glomerular filtration*efficacy*longstanding evidence base*min week*physical activity goal*goal metformin monotherapy*glucophage*medication*weight loss*ml min*lower gfr range*counseling setting*filtration rate gfr*week minimum*observational*m2*most patient*goal metformin*lifestyle change*cardiovascular event*metformin monotherapy*glomerular*metformin*gfr*longstanding evidence*min week minimum*contraindication*lower gfr*glycemic*lifestyle effort*observational data*evidence base*glycemic goal metformin*longstanding*gfr range
inhibitor glp1 analog*sulfonylurea dpp4*dpp4 inhibitor glp1*metabolic ketosis*postprandial hypoglycemia*study grade*regimen*dpp4 inhibitor*dpp iv*sulfonylurea*basal*inhibitor*hyperglycemia*irregular meal*glucagon like peptide*irregular meal schedule*hypoglycemia*drug class sulfonylurea*major drug class*insulin*sulfonylurea dpp4 inhibitor*glycemic effect*comparative effectiveness*other drug*glp1 analog*secretagogues meglitinides*secretagogues*late postprandial hypoglycemia*class sulfonylurea dpp4*effectiveness study grade*analog*catabolic feature*medical psychosocial*insulin a chain*ketosis*glycemia reduction approach*loss ketosis*high cost*ongoing glycemia reduction*dpp4*inhibitor glp1*economic outcome*specific situation*glucose toxicity*reduction approach*efficacy*feature weight loss*glucose (beta-d)-isomer*ketonuria*health economic outcome*basal insulin*iletin*weight loss ketosis*catabolic*ongoing glycemia*insulin b chain*meglitinides*meal schedule*drug class*acetonemia*glp1*combination regimen*glucose (alpha-d)-isomer*dpp 4*glycemic control*anhydrous dextrose*glucose (dl)-isomer*comparative effectiveness study*moderate glycemic effect*dipeptidyl peptidase*psychosocial*sodium insulin*catabolic feature weight*novolin*fasting hypoglycemia*postprandial*newer agent*glucose monohydrate*weight loss*glucose*class sulfonylurea*glp 1*major drug*feature weight*moderate glycemic*effectiveness study*glycemia reduction*glucose (l)-isomer*glycemic*diabetes*glycemia
hba1c*glargine*sulfonylurea dpp4*adjunctive*insulin dosing*dpp4 inhibitor glp1*pioglitazone*bolus*postprandial hypoglycemia*regimen*pharmacodynamic profile*dpp4 inhibitor*glp1 receptor agonist*dpp iv*sulfonylurea*progressive nature*basal*inhibitor*serial lung function*complex insulin regimen*postprandial glucose excursion*agonist*suboptimal blood glucose*postprandial glucose*suboptimal blood*glucagon like peptide*nph*complex insulin*glucose excursion*hypoglycemia*basal insulin analog*bolus insulin dosing*insulin*lispro*lung function testing*pharmacodynamic*sulfonylurea dpp4 inhibitor*insulin analog*dosing range*initiate insulin therapy*glucose control*limited dosing range*better absorption*injectable therapy*csii*initiate insulin*combination injectable therapy*noninsulin*insulin dos*hemoglobin a1c*insulin regimen*accurate dosing*analog*blood glucose control*prandial*u300*thiazolidinediones*dos adjunctive use*sodium glucose cotransporter*higher dos*insulin a chain*blood sugar*goal provider*smaller volume*insulin administration*longer duration*dpp4*inhibitor glp1*glycemic goal*bolus insulin*glycemic goal provider*suboptimal*glucose (beta-d)-isomer*insulin analog people*u300 glargine*basal insulin*iletin*sglt2*degludec*insulin b chain*regimen flexibility*adjunctive use*lung function*sglt2 inhibitor*limited dosing*prandial use*glp1*serial lung*u200 degludec*glucose (alpha-d)-isomer*dpp 4*a1c*function testing*noninsulin agent*concentrated preparation*anhydrous dextrose*glucose (dl)-isomer*dipeptidyl peptidase*glp1 receptor*sodium insulin*novolin*fasting hypoglycemia*postprandial*sglt 2*u200*glucose monohydrate*excursion*lower cost*injectable*part mix*blood glucose level*glucose*dosing*glp 1*acceptable fasting blood*insulin therapy*receptor agonist*biphasic*glucose (l)-isomer*glucose level*analog people*glycemic*blood glucose*diabetes*acceptable fasting
min week*metformin*agonist*weight loss*physical activity*m2*inhibitor*diabetes*glucose*medication*efficacy
